sifalimumab   Click here for help

GtoPdb Ligand ID: 8257

Synonyms: MDX-1103 | MEDI-545 | MEDI545
Immunopharmacology Ligand
Compound class: Antibody
Comment: Sifalimumab is a monoclonal antibody targeting interferon α1 (IFNA1), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE). Development of sifalimumab was terminated and MedImmune concentrated on their alternative anti-IFNα agent anifrolumab.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Sequence BLAST using the heavy and light chain variable regions of sifalimumab provides 100% matches to sequences patented with application US7741449 [12]. The sequence matches identify sifalimumab as clone 13H5 in the patent.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IFN-α2 Hs Antibody Binding 10.0 pKd - 12
⤷ pKd 10.0 (Kd 1x10-10 M) [12]
IFN-α1/13 Hs Antibody Binding 8.3 pEC50 - 12
⤷ pEC50 8.3 (EC50 4.6x10-9 M) [12]
Description: Inhibition of the antiproliferative effect of IFNA1 on Daudi cells in culture.